1. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
by Arnon P. Kater, Sabina Kersting, Yvette van Norden, Julie Dubois, Johan A. Dobber, Clemens H. Mellink, Ludo M. Evers, Fransien Croon-de Boer, John Schreurs, Ellen van der Spek, Hein Visser, Cecile Idink, Shulamiet Wittebol, Mels Hoogendoorn, Sanne H. Tonino, Mehrdad Mobasher, and Mark-David Levin
BloodAdv
Volume 2(24):
December 26, 2018
© 2018 by The American Society of Hematology

2. Arnon P. Kater et al. Blood Adv 2018;2:3566-3571
© 2018 by The American Society of Hematology

3. TLS risk mitigation after 2 preinduction cycles with obinutuzumab.
TLS risk mitigation after 2 preinduction cycles with obinutuzumab. (A) ALC at baseline and at end of preinduction per patient. (B) Largest diameter of lymph node in millimeters, as assessed by CT scan at baseline and at end of preinduction per patient. (C) Per patient change in TLS risk category; 3 = high (ALC ≥25 × 109/L and largest diameter of all measurable lymph nodes ≥5 cm and <10 cm or largest diameter of all measurable lymph nodes ≥10 cm, regardless of the ALC), 2 = intermediate (ALC ≥25 × 109/L, or largest diameter of all measurable lymph nodes ≥ 5 cm and <10 cm), 1 = low (low: absolute lymphocyte count (ALC <25 × 109/L and largest diameter of all measurable lymph nodes <5 cm).3
Arnon P. Kater et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Serial MRD results.
Serial MRD results. MRD data were obtained for 29 of 30 patients at the end of induction I (combination treatment) and 28 of 30 patients at the end induction II (venetoclax monotherapy), cycle 8 and cycle 14, respectively. Additional MRD data were obtained for 18 of 30 patients at 3 months after randomization. (A) Absolute numbers of measured MRD on peripheral blood. (B) Kinetics of MRD per patient.
Arnon P. Kater et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology